Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics, Inc. reported financial results for Q1 2024, highlighting a $40 million private placement financing, completion of enrollment in key studies, and positive clinical data. The company's cash runway extends to Q2 2026, with plans for continued program expansion and major clinical milestones. Financially, net loss decreased to $13.8 million, research and development expenses dropped, and cash and cash equivalents stood at $54.9 million at the end of March 2024.
Successful completion of a $40 million private placement financing to support ongoing operations and program expansion.
Positive clinical data presented from the Phase 2 DeFianCe study, showing promising results in CRC patients including favorable response rates and progression-free survival.
Expansion of key clinical trials, including increasing enrollment in Part B of the DeFianCe study and completion of enrollment in Part C of the DisTinGuish study.
Strong cash position with cash and cash equivalents totaling $54.9 million at the end of March 2024, and additional net proceeds from the private placement.
Net loss of $13.8 million reported for Q1 2024, though improved from the same period in 2023, was still a significant financial loss.
Decrease in research and development expenses, although positive for profitability, may raise concerns about the level of ongoing innovation and development activities.
General and administrative expenses remained relatively stable, indicating potential areas for further cost optimization.
Insights
Leap Highlights:
- Completed
private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital$40 million - Presented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC), at the 2024 ASCO Gastrointestinal Cancers Symposium
- Expanded the ongoing randomized controlled Part B of the DeFianCe study from 130 patients to 180 patients to enhance the statistical power for patients with left-sided CRC; enrollment now expected to be completed in late Q3 or early Q4 2024
- Completed enrollment in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in combination with tislelizumab and chemotherapy in patients with advanced gastroesophageal junction (GEJ) and gastric cancer; first randomized controlled data for DKN-01 expected in the second half of 2024 or early 2025
"We appreciate the strong support of Gilead and the new and existing institutional investors who participated in our recent
Business Update:
- Completed a
private placement. In April 2024, Leap entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of$40 million per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of$2.82 per share of Common Stock issuable upon exercise of the pre-funded warrants, in a private placement. Gross proceeds from the private placement were approximately$2.81 9 with participation from new and existing investors, including Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital. The net proceeds from this financing, combined with existing cash, cash equivalents and marketable securities, are expected to fund Leap's operating and capital expenditures into the second quarter of 2026 and enable expansion of the DKN-01 DeFianCe clinical trial and development program.$40 million
DKN-01 Development Update
- Presented initial clinical data from Part A of the DeFianCe Study of DKN-01 plus bevacizumab and chemotherapy in colorectal cancer (CRC) patients. The Company presented initial data from Part A of the DeFianCe study (NCT05480306), a Phase 2 study evaluating DKN-01 in combination with standard of care (SOC) bevacizumab and chemotherapy in second-line (2L) patients with advanced microsatellite stable (MSS) CRC patients at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held in
San Francisco on January 18-20, 2024 and during the Company's conference call on January 23, 2024.
- Key Findings (as of the December 6, 2023 data cutoff):
- Across all patients enrolled (n=33):
- Overall response rate (ORR) among response-evaluable patients (n=27) was
30% and disease control rate (DCR) was93% , including 8 partial responses (PR) and 17 patients with a best response of stable disease (SD) - Median progression-free survival (PFS) was 6.3 months
- 9 patients remained on therapy and were beyond 8.5 months
- Overall response rate (ORR) among response-evaluable patients (n=27) was
- Enhanced activity in patients with left-sided tumors (n=25), a group that has more frequent activation of the Wnt pathway modulated by DKK1
33% ORR and100% DCR in response-evaluable population (7 PRs, 14 SDs)- Preliminary median PFS of 8.6 months (9 patients continuing therapy within subgroup)
- Compelling ORR, DCR and PFS in patients with rectal/rectosigmoid carcinomas (n=15), a population with increasing incidence among young people and shown to have the highest
DKK1 levels:46% ORR and100% DCR in response-evaluable population (6 PRs, 7 SDs)- Preliminary median PFS of 9.4 months (6 patients continuing therapy within subgroup)
- Higher baseline plasma
DKK1 levels correlated with improved responses
- Across all patients enrolled (n=33):
- DKN-01 plus bevacizumab and chemotherapy was well-tolerated, with a majority of DKN-01 related events being low grade (Grade 1/2)
- Part B of the DeFianCe Study of DKN-01 plus bevacizumab and chemotherapy in CRC patients is ongoing, with enrollment expanded to 180 patients and expected to be completed in late Q3/early Q4 2024. The Company expanded the randomized controlled Part B of the DeFianCe study from 130 to 180 patients and included PFS in the subpopulation of patients with left-sided CRC as an additional primary endpoint. The Company expects to complete enrollment in late Q3 or early Q4 2024 with data expected in mid-2025. As of May 8, 2024, 114 patients have enrolled in Part B.
- Completion of enrollment in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer. Part C of the DisTinGuish study (NCT0436380) is a Phase 2, randomized, open-label, multicenter study of DKN-01 in combination with tislelizumab and chemotherapy in first-line patients with advanced gastroesophageal adenocarcinoma. Part C enrolled 170 first-line, HER2-negative patients randomized 1:1 to evaluate DKN-01 in combination with tislelizumab and SOC chemotherapy, compared to tislelizumab and SOC chemotherapy alone. The primary objective is PFS in
DKK1 -high and in all patients. Secondary objectives of Part C include OS and ORR as measured by RECIST v1.1 inDKK1 -high and in all patients. The Company expects to report initial data from Part C of the DisTinGuish study in the second half of 2024 or early 2025 when the PFS data are mature.
Selected First Quarter 2024 Financial Results
Net Loss was
Research and development expenses were
General and administrative expenses were
Cash and cash equivalents totaled
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements.
All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates; the anticipated expansion of the DeFianCe study and timing for completion of clinical trials and release of clinical trial data and the expectations surrounding the outcomes thereof; Leap's future clinical or preclinical product development plans for any of Leap's product candidates; Leap's estimations of projected cash runway; the anticipated closing date of the private placement; the amount of proceeds to be received by Leap and Leap's intended use of proceeds from the private placement; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully execute its clinical trials and the timing of enrollment in and cost of such clinical trials; (ii) the results of Leap's clinical trials and pre-clinical studies; (iii) Leap's ability to successfully enter into new strategic partnerships for DKN-01 or any of its other programs and to maintain its ongoing collaborations with BeiGene, NovaRock and Adimab; (iv) whether any Leap clinical trials and products will receive approval from the
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com
Leap Therapeutics, Inc | ||||||||||
Consolidated Statements of Operations | ||||||||||
(in thousands, except share and per share amounts) | ||||||||||
(Unaudited) | ||||||||||
Three Months Ended March 31 | ||||||||||
2024 | 2023 | |||||||||
Operating expenses: | ||||||||||
Research and development | $ 11,299 | $ 38,942 | ||||||||
General and administrative | 3,526 | 3,784 | ||||||||
Total operating expenses | 14,825 | 42,726 | ||||||||
Loss from operations | (14,825) | (42,726) | ||||||||
Interest income | 775 | 848 | ||||||||
Australian research and development incentives | 246 | 272 | ||||||||
Foreign currency loss | (16) | (307) | ||||||||
Change in fair value of Series X preferred stock warrant liability | - | 50 | ||||||||
Net loss | $ (13,820) | $ (41,863) | ||||||||
Net loss per share | ||||||||||
Basic and Diluted | $ (0.51) | $ (3.24) | ||||||||
Weighted average common shares outstanding | ||||||||||
Basic and diluted | 27,014,100 | 12,934,427 |
Leap Therapeutics, Inc | ||||||||||
Consolidated Balance Sheets | ||||||||||
(in thousands, except share and per share amounts) | ||||||||||
March 31, | December 31, | |||||||||
2024 | 2023 | |||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ 54,921 | $ 70,643 | ||||||||
Research and development incentive receivable | 738 | 771 | ||||||||
Prepaid expenses and other current assets | 526 | 183 | ||||||||
Total current assets | 56,185 | 71,597 | ||||||||
Property and equipment, net | - | 5 | ||||||||
Right of use assets, net | 577 | 257 | ||||||||
Research and development incentive receivable, net of current portion | 245 | - | ||||||||
Deferred costs | 39 | - | ||||||||
Deposits | 917 | 966 | ||||||||
Total assets | $ 57,963 | $ 72,825 | ||||||||
Liabilities and Stockholders' Equity | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | $ 5,951 | $ 6,465 | ||||||||
Accrued expenses | 4,056 | 5,957 | ||||||||
Lease liability - current portion | 430 | 262 | ||||||||
Total current liabilities | 10,437 | 12,684 | ||||||||
Non current liabilities: | ||||||||||
Lease liability, net of current portion | 154 | - | ||||||||
Total liabilities | 10,591 | 12,684 | ||||||||
Stockholders' equity: | ||||||||||
Preferred stock, | - | - | ||||||||
Common stock, | 26 | 26 | ||||||||
Additional paid-in capital | 460,868 | 459,591 | ||||||||
Accumulated other comprehensive income (loss) | (120) | 106 | ||||||||
Accumulated deficit | (413,402) | (399,582) | ||||||||
Total stockholders' equity | 47,372 | 60,141 | ||||||||
Total liabilities and stockholders' equity | $ 57,963 | $ 72,825 |
Leap Therapeutics, Inc | ||||||||||
Condensed Consolidated Statements of Cash Flows | ||||||||||
(in thousands) | ||||||||||
(Unaudited) | ||||||||||
Three Months Ended March 31, | ||||||||||
2024 | 2023 | |||||||||
Cash used in operating activities | $ (15,516) | $ (12,700) | ||||||||
Cash provided by investing activities | - | 49,317 | ||||||||
Cash provided by (used in) financing activities | 29 | (29) | ||||||||
Effect of exchange rate changes on cash and cash equivalents | (235) | (50) | ||||||||
Net increase (decrease) in cash and cash equivalents | (15,722) | 36,538 | ||||||||
Cash and cash equivalents at beginning of period | 70,643 | 65,500 | ||||||||
Cash and cash equivalents at end of period | $ 54,921 | $ 102,038 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-reports-first-quarter-2024-financial-results-302142971.html
SOURCE Leap Therapeutics, Inc.
FAQ
What was the net loss reported for Q1 2024?
What is Leap Therapeutics' stock symbol?
What positive clinical results were presented by Leap Therapeutics in Q1 2024?
What was the purpose of the $40 million private placement financing?